Finecure Pharmaceuticals Limited has been recognized with The Economic Times Best Healthcare Brands 2019 Award.
Finecure Pharmaceuticals Limited is leading manufacturers and marketers of Pharmaceutical formulations and Nutraceuticals in several therapeutic segments in dosage forms of Tablets, Capsules, Oral Liquids, Dry Syrup, Powders, Injections, Sachet and Effervescent. The company is WHO GMP certified and also certified for ISO 9001: 2008, ISO 22000: 2005, ISO 14001: 2004, OHSAS 18001: 2007 quality systems towards High Product Quality Assurance, Environment Management System, Occupational Health and safety.
Finecure has several accolades to its credit including:-
The Arch of Europe Award 2012,
Assocham India Business Excellence Award 2013,
Asia's Most Promising Brand 2013-2014,
UBM - IPE Fastest Growing Pharma Company Award 2015 By Union Minister Dr. Harsh Vardhan,
MEDCON - Pharma Company of the Year 2016,
Brand Excellence award 2016 by ABP News healthcare leadership awards
Best Asian Healthcare Brands, 2017 Recognition for delivering Excellence in Healthcare at India UAE Conclave
Asia Pharma Excellence Award for pharma company of the Year 2017
CIMS Healthcare Excellence Award 2017 for Pharma Company of the Year in Penicillin.
Dream Companies to work for Pharmaceuticals 2017 World HRD Congress
The Company is poised for vertical growth, with modern facilities, skills and knowhow and resources that are at par with the best in the country. The company has state-of-the-art manufacturing facilities and maintains all specific set of standards mandated by the Food and Drug Administration (FDA). The company is certified for WHO GMP, ISO 9001, ISO 22000, ISO 14001, OHSAS 18001 quality systems towards High Product Quality Assurance, Environment Management System, Occupational Health and safety. The company has received recognitions from prestigious organizations like FICCI, ASSOCHAM, IDMA and Pharmexcil acknowledging their excellence in the pharmaceutical market. The Company is CRISIL 1A rated towards "Highest Performance Capability". The company registered a compounded annual growth rate (CAGR) of 32.95 per cent in revenue from 2012-13 to 2016-17 as against average industry CAGR between 12 to 14%.